Gordon L Sussman Selected Research

Gordon L Sussman Research Topics

3	Hypersensitivity (Allergy) 12/2016 - 08/2002
3	Chronic Urticaria 03/2014 - 10/2002
2	Food Hypersensitivity (Food Allergy) 02/2024 - 01/2014
2	Hereditary Angioedemas 01/2023 - 01/2017
2	Angioedema 01/2023 - 01/2014
2	Peanut Hypersensitivity (Peanut Allergy) 01/2021 - 11/2017
2	Conjunctivitis 01/2018 - 12/2016
2	Asthma (Bronchial Asthma) 01/2018 - 12/2016
2	Allergic Rhinitis 01/2018 - 12/2016
2	Anaphylaxis (Anaphylactic Shock) 01/2016 - 05/2002
2	Spinal Dysraphism (Spina Bifida) 08/2005 - 08/2002
2	Latex Hypersensitivity (Latex Allergy) 08/2005 - 08/2002
1	Milk Hypersensitivity (Milk Allergy) 02/2024
1	Acquired angioedema 01/2023
1	Cardiotoxicity 12/2022
1	Rhinitis 12/2016
1	AIDS-Related Complex (ARC) 01/2015
1	Fatigue 01/2014
1	Autoimmune Diseases (Autoimmune Disease) 01/2014
1	Neoplasms (Cancer) 01/2014
1	Urticaria (Hives) 05/2002
1	Dermatitis 05/2002
1	Occupational Asthma 05/2002

5	AllergensIBA 02/2024 - 08/2002
4	Immunoglobulin E (IgE)IBA 02/2024 - 05/2002
3	TabletsIBA 01/2018 - 01/2015
3	Proteins (Proteins, Gene)FDA Link 08/2005 - 05/2002
2	KininsIBA 01/2023 - 01/2014
2	Monoclonal AntibodiesIBA 01/2023 - 01/2023
2	LatexIBA 08/2005 - 08/2002
2	Rubber (Elastica)IBA 08/2005 - 08/2002
1	Complement Inactivating AgentsIBA 01/2023
1	Histamine (Histamine Dihydrochloride)FDA Link 01/2023
1	Factor XIIa (Coagulation Factor XIIa)IBA 01/2023
1	A-factor (Streptomyces)IBA 01/2023
1	BradykininIBA 01/2023
1	Complement System Proteins (Complement)IBA 01/2023
1	Bradykinin Receptor AntagonistsIBA 01/2023
1	Histamine Antagonists (Antihistamines)IBA 12/2022
1	Diphenhydramine (Benadryl)FDA LinkGeneric 12/2022
1	Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)IBA 01/2017
1	Epinephrine (Adrenaline)FDA LinkGeneric 12/2016
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2016
1	Ketotifen (Ketotifene)FDA Link 01/2014
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2014
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2014
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2014
1	Omalizumab (Xolair)FDA Link 02/2013
1	2,5-dichloro-4-bromophenol (B 2)IBA 08/2005
1	AntibodiesIBA 10/2002
1	Indicators and Reagents (Reagents)IBA 08/2002
1	PowdersIBA 05/2002
1	Irritants (Vesicants)IBA 05/2002

4	Immunotherapy 02/2024 - 01/2014
4	Therapeutics 01/2023 - 02/2013